We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Provepharm and Martindale Pharma® Announce Partnership

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Provepharm and Martindale Pharma® Announce Partnership"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Provepharm and Martindale Pharma have announced that they have entered into an exclusive partnership, to supply Provepharm’s injectable medicinal product, methylthioninium chloride Proveblue solution for injection (Proveblue™), for the treatment of medicinal and chemical products - induced methaemoglobinaemia in the UK and Ireland.

Under the agreement, Martindale Pharma will be responsible for all commercial activities relating to Proveblue in the UK and Ireland. Commercial terms of the deal were not disclosed.

The Proveblue medicinal product, which was developed by Provepharm starting from its methylthioninium chloride active substance was the first methylene blue to meet the European Pharmacopeia standards.

It gained the first approval by the European Medicines Agency in May 2011 and represents a significant improvement in quality from current methylthioninium chloride products.

Methaemoglobinaemia is a life-threatening blood disorder characterized by an abnormal amount of methaemoglobin in the blood, leading to an inability to release oxygen to body tissue effectively.

The disorder can be inherited or acquired after exposure to certain chemicals or drugs, for example anaesthetics, and certain antibiotics and nitrites which are used in the preservation of food.

The Proveblue medicinal product has enhanced purity in comparison with Martindale’s previous methylthioninium chloride product, which only reached the United States Pharmacopeia (USP) standard.

Additional benefits of Proveblue include a new indication for chemical products-induced methaemoglobinaemia, as well as acute symptomatic treatment of medicinal methaemoglobinaemia and the indication to treat children and adolescents (aged 0-17 years old) as well as adults.

Michel Féraud, CEO and founder of Provepharm, commented: “We are pleased to be collaborating with Martindale Pharma which has such a good understanding of our market in the UK and Ireland and we appreciate Martindale’s decision to switch to Proveblue as a move to enhance quality for patients.”

Richard de Souza, CEO, Martindale Pharma, commented: “We are delighted to be collaborating with Provepharm on Proveblue, with whom we share similar values and goals. This provides a solid platform for the launch and success of the Proveblue medicinal product in the UK and Ireland.”